Abstract: The present disclosure relates generally to stapled peptides, and pharmaceutical compositions thereof, which are useful for preventing and/or treating herpes simplex virus-1 (HSV-1) processive DNA synthesis, propagation, and/or infection in a subject.

Abstract: This invention provides compounds of formulas (I)-(XIV) as defined in the specification, and pharmaceutical compositions comprising the same, and methods of inhibiting, treating, or abrogating a molluscum contagiosum virus infection in a subject using compounds or compositions of the invention:

Abstract: This invention provides compounds of formulas (I)-(XIV) as defined in the specification, and pharmaceutical compositions comprising the same, and methods of inhibiting, treating, or abrogating a molluscum contagiosum virus infection in a subject using compounds or compositions of the invention:

Abstract: This invention provides compounds of formulas (I), (II), (III), and (IV) as defined in the specification, and pharmaceutical compositions comprising the same, and methods of inhibiting, treating, or abrogating a poxvirus infection in a subject using the compounds or compositions.

Abstract: This invention provides methods of inhibiting replication of a poxvirus by contacting a poxvirus with a compound having formula I, formula XXI, formula XXXII, or formula XLI which in turn reduce, inhibit, or abrogate poxvirus DNA polymerase activity and/or its interaction with its processivity factor. Formula I, formula XXI, formula XXXII, or formula XLI can be utilized to treat humans and animals suffering from a poxvirus infection. Pharmaceutical compositions for treating poxvirus infected subjects are also provided.

Abstract: This invention provides compounds of formulas (I), (II), (III), and (IV) as defined in the specification, and pharmaceutical compositions comprising the same, and methods of inhibiting, treating, or abrogating a poxvirus infection in a subject using the compounds or compositions.

Abstract: The invention relates to kits and methods for assessing the desirability of supplementing the diet of a human with reduced coenzyme Q (CoQH2). The methods involve assessing occurrence in the human's genome of the NQO1*2 polymorphism of the NQO1 gene. Occurrence of a copy of the polymorphism indicates that the human can benefit from dietary supplementation with CoQH2, and occurrence of two copies (i.e., homozygosity) of the NQO1*2 polymorphism indicates that dietary supplementation with CoQH2 can be especially desirable.

Abstract: The invention relates to kits and methods for assessing the susceptibility of a human to oxidative stress or damage. The methods involve assessing occurrence in the human's genome of one or more polymorphisms (e.g., single nucleotide polymorphisms) that occur in one or more genes associated with oxidative stress and that are associated with a disorder in humans. Preferred assessment and scoring methods are disclosed, as are kit for performing the methods.

Abstract: This invention provides methods of inhibiting replication of a poxvirus by contacting a poxvirus with a compound having formula I, formula XXI, formula XXXII, or formula XLI which in turn reduce, inhibit, or abrogate poxvirus DNA polymerase activity and/or its interaction with its processivity factor. Formula I, formula XXI, formula XXXII, or formula XLI can be utilized to treat humans and animals suffering from a poxvirus infection. Pharmaceutical compositions for treating poxvirus infected subjects are also provided.

Abstract: This invention provides methods of inhibiting replication of a poxvirus by contacting a poxvirus with a compound having formula I, formula XXI, formula XXXII, or formula XLI which in turn reduce, inhibit, or abrogate poxvirus DNA polymerase activity and/or its interaction with its processivity factor. Formula I, formula XXI, formula XXXII, or formula XLI can be utilized to treat humans and animals suffering from a poxvirus infection. Pharmaceutical compositions for treating poxvirus infected subjects are also provided.

Abstract: The invention relates to kits and methods for assessing the susceptibility of a human to oxidative stress or damage. The methods involve assessing occurrence in the human's genome of one or more polymorphisms (e.g., single nucleotide polymorphisms) that occur in one or more genes associated with oxidative stress and that are associated with a disorder in humans. Preferred assessment and scoring methods are disclosed, as are kit for performing the methods.

Abstract: This invention provides methods of inhibiting replication of a poxvirus by contacting a poxvirus with a compound having formula I, formula XXI, formula XXXII, or formula XLI which in turn reduce, inhibit, or abrogate poxvirus DNA polymerase activity and/or its interaction with its processivity factor. Formula I, formula XXI, formula XXXII, or formula XLI can be utilized to treat humans and animals suffering from a poxvirus infection. Pharmaceutical compositions for treating poxvirus infected subjects are also provided.

Abstract: The invention relates to kits and methods for assessing skin health for a human and the human's susceptibility to skin disorders. The methods involve assessing occurrence in the human's genome of one or more polymorphisms (e.g., single nucleotide polymorphisms) that occur in one or more genes associated disclosed herein and that are associated with a disorder in humans. Preferred assessment and scoring methods are disclosed, as are kits for performing the methods.

Abstract: This invention provides methods of inhibiting replication of a poxvirus by contacting a poxvirus with a compound having formula XVII which in turn reduce, inhibit, or abrogate poxvirus DNA polymerase activity and/or its interaction with its processivity factor. Formula XVII can be utilized to treat humans and animals suffering from a poxvirus infection. Pharmaceutical compositions for treating poxvirus infected subjects are also provided.

Abstract: The present invention relates to methods for assessing the advisability that a human should employ a compensatory composition comprised of one or more antioxidant ingredients. The methods involve assessing occurrence in the human's genome of a plurality of certain polymorphisms. Methods for determining the composition of preferred compensatory compositions are also disclosed.

Abstract: The invention relates to kits and methods for assessing the susceptibility of a human to oxidative stress or damage. The methods involve assessing occurrence in the human's genome of one or more polymorphisms (e.g., single nucleotide polymorphisms) that occur in one or more genes associated with oxidative stress and that are associated with a disorder in humans. Preferred assessment and scoring methods are disclosed, as are kit for performing the methods.

Abstract: The invention relates to kits and methods for assessing the desirability of supplementing the diet of a human with reduced coenzyme Q (CoQH2). The methods involve assessing occurrence in the human's genome of the NQO1*2 polymorphism of the NQO1 gene. Occurrence of a copy of the polymorphism indicates that the human can benefit from dietary supplementation with CoQH2, and occurrence of two copies (i.e., homozygosity) of the NQO1*2 polymorphism indicates that dietary supplementation with CoQH2 can be especially desirable.

Abstract: The present invention relates to methods for assessing the advisability that a human should employ a compensatory composition comprised of one or more antioxidant ingredients. The methods involve assessing occurrence in the human's genome of a plurality of certain polymorphisms. Methods for determining the composition of preferred compensatory compositions are also disclosed.

Abstract: This invention provides methods of inhibiting replication of a poxvirus by contacting a poxvirus with a compound having formula I, formula XXI, formula XXXII, or formula XLI which in turn reduce, inhibit, or abrogate poxvirus DNA polymerase activity and/or its interaction with its processivity factor. Formula I, formula XXI, formula XXXII, or formula XLI can be utilized to treat humans and animals suffering from a poxvirus infection. Pharmaceutical compositions for treating poxvirus infected subjects are also provided.

Abstract: The disclosure relates to kits and methods for assessing whether an individual is likely to benefit from nutritional supplementation with coenzyme Q and, more particularly, a reduced form of coenzyme Q. The methods involve assessing occurrence of a polymorphism in the gene encoding NQO1 in the individual. Individuals homozygous for the polymorphism will receive optimal benefits from supplementation with the reduced form of coenzyme Q. The disclosure further relates to methods for predicting and assigning a coenzyme Q redox status phenotype based on assessment of an individual's genome for a polymorphism in the gene encoding NQO1.